Neck-and-Neck in Nephrology
Nabi with PhosLo and Genzyme with Renagel now split the market for dialysis patients requiring treatment for high phosphate levels. Soon a third firm will enter the fray--the UK's Shire. Thus far, the marketing battle has been fought with nitty-gritty clinical data. But now Genzyme is raising the notion of "accumulation" to stigmatize competitors, while Nabi emphasizes the issue of cost. The competitive stakes are rising because Medicare changes in 2006 will dramatically expand the market.
You may also be interested in...
Ilypsa is a spin-out of Symyx Technologies, a manufacturer of innovative materials for such industrial clients such as Dow Chemical and Agfa-Gevaert. The company had honed an ability to rapidly screen miniscule amounts of thousands of polymers for interesting functions. Symyx's founders quickly recognized that the company's platform was a potential therapeutic gold mine. Ilypsa was thus founded to focus on pharmaceutical applications.
Teva has launched the first and so far only US generic version of Novartis’ Azopt treatment for ocular hypertension, with the brinzolamide 1% solution having been developed and manufactured by Indoco Remedies.